Lazard Asset Management
JNCE

Lazard Asset Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Lazard Asset Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,095
Closed -$89K – 2507
2021
Q3 		$89K Buy
+12,095
New +$74.9K ﹤0.01% 1459
2021
Q2 		– Sell
-5,453
Closed -$56K – 2123
2021
Q1 		$56K Buy
+5,453
New +$59.7K ﹤0.01% 1391
2020
Q1 		– Sell
-505
Closed -$4K – 1797
2019
Q4 		$4K Buy
+505
New +$2.73K ﹤0.01% 1447

Other funds holding JNCE

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Lazard Asset Management's JNCE Position: Q4 2021 in Review

Lazard Asset Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2021, closing a stake of 12,095 shares — an estimated $89K sold.

Lazard Asset Management first reported a position in JNCE in Q4 2019 and held it in 3 quarters. The position peaked at $89K in Q3 2021. 124 funds tracked by Wall St. Rank hold JNCE as of Q4 2021.

  • Lazard Asset Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Lazard Asset Management sold 12,095 Jounce Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $89K.
  • Lazard Asset Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
  • Lazard Asset Management's Jounce Therapeutics, Inc. Common Stock position peaked at $89K in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Lazard Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.